• Atropo-Enantioselective Suzuki Synthesis

  2026-09-01

  Herrbach and co-workers developed a catalytic atropo-enantioselective Suzuki coupling to construct the axially chiral biaryl core of an antimitotic rhazinilam analogue. Ligand screening identified a binaphthyl phosphine that provided up to 40% enantiomeric excess, establishing an important proof of concept while also exposing the limitations of asymmetric control in this biologically relevant scaffold.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-08-31

  A 2024 bioRxiv preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can also expose the activation-loop phosphothreonine to the phosphatase WIP1. The structural and biochemical findings introduce conformational control of dephosphorylation as a potential route to more durable and selective kinase pathway inhibition.

• TPPU: A Practical sEH Assay Decision Framework

  2026-08-31

  TPPU is a potent soluble epoxide hydrolase inhibitor for dissecting fatty acid epoxide signaling in inflammatory pain and bone biology. This article presents a compartment-aware assay strategy that connects target engagement, lipid mediator measurements, Nrf2-linked phenotypes, and translational limitations.

• SPOP Molecular Glue Degradation in Melanoma Immunotherapy

  2026-08-30

  The reference study identifies SPOP as a melanoma-promoting E3 ligase that degrades the innate immune sensor STING, thereby limiting interferon signaling. It further shows that SPOP inhibitors can act as molecular glues, redirecting SPOP toward CBX4 and enhancing STING-dependent responses that improve checkpoint blockade and CAR-T treatment in preclinical models.

• YM 58483 (BTP2): SOCE Blocker for Ca2+ Research

  2026-08-29

  YM 58483, also called BTP2, is a store-operated Ca2+ entry inhibitor that suppresses sustained calcium influx through CRAC and TRP channels. Product data report approximately 17 nM inhibition of PHA-induced IL-2 production, while a 2025 salivary-gland study used YM58483 to investigate ORAI2-dependent postirradiation fibrosis.

• Methylprednisolone in Steroid-Induced Bone Loss

  2026-08-28

  Methylprednisolone is more than an inflammation-inducing reagent: it is a translational tool for connecting glucocorticoid receptor biology with osteoclast activity, vascular compromise, and femoral-head preservation. This article interprets a rat model of glucocorticoid-induced osteonecrosis and outlines a practical workflow for mechanistic and translational researchers.

• Oridonin Protects Bone Through MAPK/NF-κB Signaling

  2026-08-28

  The 2023 reference study shows that oridonin counteracts thioacetamide-induced bone injury through a dual mechanism: suppressing osteoclastogenesis via MAPK/NF-κB signaling while restoring osteoblast-associated BMP-2/RUNX2 activity. Its paired osteoclast and osteoblast models provide a useful framework for studying therapies that address both excessive bone resorption and impaired bone formation.

• SD 169: A State-Aware p38 MAPK Assay Strategy

  2026-08-27

  SD 169 (indole-5-carboxamide) is a selective p38α/β inhibitor for dissecting inflammatory, metabolic, and neural signaling. This article explains how activation-loop dephosphorylation findings can improve assay design and interpretation beyond simple pathway inhibition.

• Bufalin: A Degrader-Led Roadmap for TNBC

  2026-08-27

  A translational roadmap for positioning Bufalin as a mechanistically informative cardiotonic steroid in triple-negative breast cancer research, integrating STK33 target degradation, assay design, model selection, competitive differentiation, and practical workflow guidance.

• Bacillus Media Shape γ-Glutamyl Peptide Production

  2026-08-26

  The reference study shows that both Bacillus strain identity and growth-medium composition influence γ-glutamyl peptide production, with hemoglobin hydrolysate generally favoring higher peptide concentrations while brain heart infusion selectively supported detectable glutathione formation. Its main practical contribution is a comparative framework for linking substrate composition, amino-acid availability, bacterial growth, and γ-glutamyltransferase activity in microbial flavor and glutathione metabolism research.

• Forskolin for cAMP-Driven Cell Assays

  2026-08-26

  Forskolin provides a direct route to elevate cAMP, making it useful for pathway perturbation, regenerative cell culture, secretion studies, and inflammation-focused assays. This guide translates its mechanism into practical workflows, dose-finding strategies, and troubleshooting decisions anchored to a corneal epithelial culture study.

• JNK-IN-7 for State-Resolved Apoptosis Assays

  2026-08-25

  JNK-IN-7 enables selective JNK inhibition while preserving a pathway-resolved view of infection-associated apoptosis. This article translates Candida krusei findings into practical assay decisions, including c-Jun phosphorylation, mitochondrial, death-receptor, and innate immune readouts.

• JNK-IN-7: From JNK Mechanism to Translational Insight

  2026-08-25

  A thought-leadership analysis of how JNK-IN-7 can connect covalent kinase biology with infection-associated apoptosis, innate immune signaling, and translational assay design.

• Entinostat (MS-275) for HDAC Research Workflows

  2026-08-24

  Entinostat, also known as MS-275 or SNDX-275, provides a selective class I HDAC platform for connecting histone-acetylation measurements with cancer-cell phenotypes. This guide translates evidence from oncology and axolotl regeneration research into practical assay design, controls, and troubleshooting strategies.

• Toremifene: A Mechanism-First Assay Strategy

  2026-08-24

  Toremifene enables a mechanism-first approach to prostate cancer research by separating estrogen receptor effects from STIM1-dependent calcium and metastatic phenotypes. This article translates recent TSPAN18–STIM1 findings into practical, better-controlled assay decisions.

8612 records 2/575 page Previous Next 12345 下5页 Last page